Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion

The company allocated €56 million to research and development for next-generation line solutions

Bayer flags major Phase III results for stroke prevention drug asundexian

The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy

FDA presses 2,200+ companies to fix missing clinical trial results

Move amid evidence of widespread reporting gaps

Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial

Safety was equally impressive. ENV-294 was well tolerated

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred

Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma

The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume

Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy

The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract

New diabetes drug UBT251 shows strong phase 2 results in China

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

The company plans to submit the vaccine for regulatory review